VolitionRx to Attend Several Conferences in September

NAMUR, Belgium, Sept. 7, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that its Chief Executive Officer, Cameron Reynolds, and its Vice President of Investor Relations, Scott Powell, are scheduled to attend and present at several conferences in September.

During their presentations, Mr. Reynolds and Mr. Powell will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced European commercialization strategy for its Nu.Q blood-based tests for colorectal cancer.

Details of the conferences are as follows:

Conference:

2016 Wells Fargo Healthcare Conference

Date:

Thursday, September 8, 2016

Location:

The Westin Boston Waterfront, Boston



Conference:

Rodman & Renshaw 18th Annual Global Investment Conference

Date:

Monday, September 12, 2016

Time:

12:05 p.m. EDT

Location:

Lotte New York Palace Hotel, New York City



Conference:

17th Annual GCFF Toronto Conference 2016

Date:

Saturday, September 17, 2016

Time:

10:45 a.m. EDT

Location:

Courtyard Toronto Northeast/Markham, Markham, ON



Conference:

2016 Aegis Growth Conference

Date:

Wednesday, September 21, 2016

Time:

1:00 p.m. PDT

Location:

The Encore at Wynn, Las Vegas



Conference:

MicroCap Leadership Summit

Date:

Friday, September 23, 2016

Time:

8:30 a.m.-4:00 p.m. CDT (Small Group Presentations)

Location:

Westin Chicago Northwest Hotel, Itasca, IL

Persons attending the conferences who would like to schedule a 1-on-1 meeting with Volition management during the conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com  or Scott Powell, Vice President of Investor Relations of Volition, at S.Powell@volitionrx.com

About Volition

Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit Volition's website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.

 

Media / Investor Contacts




Louise Day, Volition

Scott Powell, Volition

L.Day@volitionrx.com 

S.Powell@volitionrx.com

+44 (0)7557 774 620

+1 (646) 650-1351



 

Tirth Patel, Edison Advisors

 

Katherine Fennell, Edison Advisors

tpatel@edisongroup.com 

kfennell@edisongroup.com

+1 (646) 653-7035 

+44 (0) 20 7841 1556

Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-to-attend-several-conferences-in-september-300322952.html

SOURCE VolitionRx Ltd

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus